Dyne Therapeutics

Overview

Dyne Therapeutics is a clinical-stage biotechnology company based in Waltham, Massachusetts, dedicated to developing targeted therapeutics for serious neuromuscular diseases. Founded in 2017, the company utilizes its proprietary FORCE™ platform to deliver disease-modifying oligonucleotide therapies directly to muscle tissue and the central nervous system, with the goal of halting or reversing disease progression.

The company's pipeline includes investigational therapies for conditions such as Myotonic Dystrophy Type 1, Duchenne Muscular Dystrophy, and Facioscapulohumeral Muscular Dystrophy, among others. Its FORCE™ platform enhances the delivery of therapeutic oligonucleotides by conjugating them with antibodies, improving their efficiency and specificity to muscle cells. Dyne Therapeutics is committed to advancing innovative treatments through rigorous clinical trials and collaborations, working closely with regulatory agencies to bring its therapies to patients in need.

Basic Information

Contact Details

• Phone: +1 781-786-8230
• Website: dyne-tx.com
• LinkedIn: linkedin.com/company/dynetx

Key Focus Areas & Initiatives

• Biotechnology: pharmaceutical preparations
• Health care
• Biotechnology research
• Drug development
• Molecular conjugates
• Molecular targeting
• Biotechnology
• FSHD DUX4 targeting
• Environmental sustainability
• Clinical trials
• Enzyme replacement therapy
• Services
• Targeted therapies
• Muscle delivery
• Gene therapy delivery
• Therapeutic conjugates
• Personalized medicine
• Antisense conjugates
• Clinical-stage biotech
• Re-dosing potential
• DMD therapies
• Antisense oligonucleotides
• Targeted drug delivery
• Pompe disease treatments
• Gene silencing
• Biopharmaceuticals
• Pompe enzyme therapy
• Biotech for rare diseases
• Research and development in the physical, engineering, and life sciences
• Targeted therapeutics
• Rare disease drug development
• Therapeutic payloads
• CNS delivery
• Muscle and CNS delivery
• Targeted oligonucleotides
• Patient advocacy
• Biotech innovation
• Rare neuromuscular disorders
• Biotech leadership
• TFR1 targeting
• Muscle-specific delivery
• siRNA
• Payload conjugation
• Disease-modifying treatments
• DMPK knockdown
• RNA foci reduction
• Medical research
• Muscle transcriptomics
• Neuromuscular diseases
• DUX4 suppression
• Pharmaceuticals
• DM1 therapies
• Healthcare
• RNA splicing correction
• siRNA therapies
• Rare disease therapeutics
• B2B
• Drug discovery
• FSHD programs
• FORCE platform
• Genetically driven diseases
• Genetic neuromuscular diseases
• DMD exon skipping
• Exon skipping
• Nucleic acid therapies
• Rare diseases
• Muscle disease
• Muscle-targeted therapies
• Myotonic dystrophy
• Duchenne muscular dystrophy
• Facioscapulohumeral muscular dystrophy
• Antibody engineering
• Oligonucleotide therapeutics
• Antisense oligonucleotide
• Gene therapy
• Genetic diseases
• Orphan drug designation
• Functional dystrophin
• Muscle function restoration
• FDA
• European Medicines Agency
• Tissue delivery
• Safety and efficacy
• Pediatric diseases
• Disease-modifying therapies
• Community engagement
• Patient access
• Patient stories
• Genetic mutation
• Oligonucleotide design
• Therapeutic payload
• Receptor biology
• Metabolic muscle diseases
• Research collaborations
• Medical innovations
• Therapy design
• Clinical program
• Muscle biology
• Caregiver support
• Community insights
• Patient engagement
• Pharmacodynamics
• Biomarkers
• Clinical endpoints
• Muscle-related genetic disorders
• Healthcare resource utilization
• Education
• Non-profit
• Health, wellness & fitness
• Hospital & health care
• Medical
• Nonprofit organization management

Technologies Used

• AI
• Bootstrap Framework
• Google Analytics
• Google Cloud Hosting
• Google Tag Manager
• Mobile Friendly
• Nginx
• Outlook
• Remote
• Salesforce
• WP Engine
• WordPress.org
• YouTube

Affiliated Organizations & Regional Branches